Studies on the antimicrobial potential of the cardiovascular drug lacidipine

In Vivo. 2007 Sep-Oct;21(5):847-50.

Abstract

The cardiovascular drug lacidipine was screened in vitro for possible antibacterial activity with respect to 389 Gram-positive and Gram-negative bacterial strains. It was noticed that most bacteria (233) failed to grow at 50-200 microg/mL concentrations of the drug. Some strains were inhibited at even lower concentrations. The bacteria could be arranged according to their decreasing order of sensitivity as follows: Staphylococcus aureus, Vibrio cholerae, Salmonella spp., Shigellae, Escherichia coli, Bacillus spp., Klebsiellae and Pseudomonas spp. Lacidipine was found to be bacteriostatic in nature against S. aureus and V cholerae. When administered to Swiss strain of white mice at doses of 30 and 60 microg/mouse, lacidipine significantly protected the animals challenged with 50 MLD of S. typhimurium NCTC 74. According to the chi-square test, the in vivo data were highly significant (p<0.001).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Bacterial Agents / chemistry
  • Anti-Bacterial Agents / pharmacology*
  • Anti-Bacterial Agents / therapeutic use
  • Cardiovascular Agents / chemistry
  • Cardiovascular Agents / pharmacology*
  • Cardiovascular Agents / therapeutic use
  • Dihydropyridines / chemistry
  • Dihydropyridines / pharmacology*
  • Dihydropyridines / therapeutic use
  • Gram-Negative Bacteria / drug effects
  • Gram-Positive Bacteria / drug effects
  • Male
  • Mice
  • Molecular Structure
  • Salmonella Infections / drug therapy
  • Salmonella Infections / microbiology
  • Toxicity Tests

Substances

  • Anti-Bacterial Agents
  • Cardiovascular Agents
  • Dihydropyridines
  • lacidipine